Livzon Pharmaceutical Group Inc. (SHE:000513)
China
· Delayed Price · Currency is CNY 34.91
+0.22 (0.63%)
Mar 10, 2026, 1:35 PM CST
SHE:000513 Revenue
Livzon Pharmaceutical Group had revenue of 2.84B CNY in the quarter ending September 30, 2025, with 1.60% growth. This brings the company's revenue in the last twelve months to 11.85B, down -0.09% year-over-year. In the year 2024, Livzon Pharmaceutical Group had annual revenue of 11.81B, down -4.97%.
Revenue (ttm)
11.85B
Revenue Growth
-0.09%
P/S Ratio
2.36
Revenue / Employee
1.31M
Employees
9,067
Market Cap
27.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.81B | -617.70M | -4.97% |
| Dec 31, 2023 | 12.43B | -199.54M | -1.58% |
| Dec 31, 2022 | 12.63B | 565.72M | 4.69% |
| Jan 1, 2022 | 12.06B | 1.54B | 14.67% |
| Jan 1, 2021 | 10.52B | 1.14B | 12.10% |
| Jan 1, 2020 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jan 1, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shijiazhuang Yiling Pharmaceutical | 6.01B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 5.37B |
| Kangmei Pharmaceutical | 5.28B |
| Chengdu Kanghong Pharmaceutical Group | 4.67B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Humanwell Healthcare (Group) | 24.18B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Dizal (Jiangsu) Pharmaceutical | 801.14M |